Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …

Natriuretic peptide [NP; B‐type NP (BNP), N‐terminal proBNP (NT‐proBNP), and
midregional proANP (MR‐proANP)] concentrations are quantitative plasma biomarkers for …

A wealth of clinical and epidemiological evidence has linked obesity to a broad spectrum of
cardiovascular diseases (CVD) including coronary heart disease, heart failure …

Background and Purpose: Natriuretic peptides have led the way as a diagnostic and
prognostic tool for the diagnosis and management of heart failure (HF). More recent …

Obesity continues to be a public health problem in the general population, and also
significantly increases the risk for the development of new-onset heart failure (HF). However …

The pro-inflammatory state of the visceral adipose tissue (VAT) is supposed to accelerate
cardiovascular (CV) and metabolic diseases in obese subjects. Some studies have recently …

Aims Although body mass index (BMI) is the most commonly used anthropometric measure,
newer indices such as the waist-to-height ratio, better reflect the location and amount of …

Clinical studies have indicated the existence of an “obesity paradox” in patients with chronic
heart failure (HF), that is, reduced mortality in patients who have elevated body mass index …

Obesity has reached epidemic proportions in the United States and worldwide. Considering
the adverse effects of obesity on left ventricular (LV) structure, diastolic and systolic function …

Obesity has reached global epidemic proportions in both adults and children and is
associated with numerous comorbidities, including hypertension (HTN), type II diabetes …